Previous work has suggested that earlier generations of EGFR inhibitors had poor affinity for the EGFR mutations found in GBM, such as the vIII truncation.7 Our data does not support this claim, with both erlotinib and WSD-0922 effectively ablating WT and mutant EGFR phosphorylation. This evidence concerns the gene EGFR and glioblastoma.